Bowen Acquisition Enters Into Merger Agreement With Shenzhen Qianzhi Biotech Company
Bowen Acquisition Enters Into Merger Agreement With Shenzhen Qianzhi Biotech Company
Pursuant to the Merger Agreement, BOWN's wholly owned subsidiary, Bowen Merger Sub, a Cayman Islands exempted company, will merge (the "Merger" or the "Business Combination") with and into Qianzhi Group Holding (Cayman) Limited, parent of Qianzhi BioTech and an exempted company incorporated with limited liability in the Cayman Islands ("NewCo"), with NewCo being the surviving company of the Merger and becoming a wholly-owned subsidiary of BOWN. In connection with the Merger, the NewCo Shareholders will receive an aggregate of 7,246,377 ordinary shares of BOWN and have the right to receive up to an additional 1,400,000 ordinary shares of BOWN upon the achievement of certain earnout targets as provided for in the Merger Agreement.
根据合并协议，BOWN的全资子公司开曼群岛豁免公司Bowen Merger Sub将与千智集团控股（开曼）有限公司合并（“合并” 或 “业务合并”），后者是千智生物的母公司，也是一家在开曼群岛注册成立的有限责任公司（“NewCo”），而NewCo是合并的幸存公司，成为BO的全资子公司 WN。与合并有关的是，NewCo股东将获得总计7,246,377股BOWN普通股，并有权在实现合并协议中规定的某些收益目标后额外获得最多140万股BOWN普通股。